(Reuters) – The U.S. Food and Drug Administration declined to approve Regeneron’s therapy for a common form of blood cancer, the company said on Tuesday.
(Reporting by Bhanvi Satija, Sneha S K and Nilutpal Timsina in Bengaluru; Editing by Shailesh Kuber)
Comments